ALSO NOTED: Novo Nordisk, Pfizer settle insulin suit; Perrigo gets OK for generic heartburn drug;

> Now that Pfizer has pulled Exubera off the market, Novo Nordisk has settled a patent lawsuit with the company over the inhaled insulin product. Novo Nordisk had alleged that Exubera was based on its own inhaled insulin treatment, which hasn't yet reached market. Release

> Perrigo says the FDA gave final approval to an over-the-counter, generic heartburn treatment the company will market in partnership with Dexcel Pharma. Report

> Hikma Pharmaceuticals has inked a deal to buy Arab Pharmaceutical Manufacturing for $163.6 million. Report

> Bristol-Myers Squibb hired computer systems giant EDS to manage its IT in the Americas and Asia. Report

> At an R&D day for analysts and investors, AstraZeneca is filling in some of the details on its move to merge two recent biotech purchases--MedImmune and Cambridge Antibody Technology (CAT). Report

> Several big developers will take the stage at the American Society of Hematology meeting to provide updates on a string of new blood thinners that are in the clinic. Report

> Trend spotter alert: GlaxoSmithKline's newly announced $1.4 billion partnership pact with OncoMed delivers fresh evidence of just how hot antibodies and the cancer field are these days. Report

> When it comes to government spending on medical research, the EU is far behind the U.S. And some of the leaders in the field say it's time to catch up--fast. Report

And Finally... Only one plan in the entire U.S. will cover the so-called doughnut hole in Medicare drug coverage this year. Report

Free Webinar

What could you do with real-time supply chain information at your fingertips?

Interested in complete supply chain real-time data visibility? Unlock productivity with digital workflows, manage plants inventory with real-time supply chain information and enable faster decision-making with data visualization with pci | bridge. Register today!

Suggested Articles

Companies considering this avenue must think through potential implications despite the obvious attraction of early access for patients.

BD says a $1.2 billion investment in its pre-filled syringe business will add surge capacity needed to meet demand in future pandemics.

Ad Environment Matters for Message Receptivity